That is exactly what I was saying. If cash was the issue that appears based on the cash on hand and burn rate, these management and board members would likely not be buying open market as they would know and have better opportunities available to them.

I still believe they need cash or will relatively soon (based on last quarterly filing), but the situation doesn’t appear to be as dire as some think. Not that I’ve been around 5+ years like some here, but this time last year was a much different financial situation for those newer to CYDY (some may remember the surprise Friday night email from MM that caused a bloody Monday last fall).

Both CytoDyn and leronlimab (largely due to BP & COVID) have advanced greatly over the past year. I expect similar advancement over the next several years. I’ll patiently wait until for 1+ approval/s and will likely still be holding many shares while watching Vyrologix/leronlimab commercials between football games one of these days.